Surf Wiki
Save to docs
general/experimental-cancer-drugs

From Surf Wiki (app.surf) — the open knowledge base

Ombrabulin

Ombrabulin was an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis. Ombrabulin is a combretastatin A-4 derivative that exerts its antitumor effect by disrupting the formation of blood vessels needed for tumor growth.

It was granted orphan drug status by the European Medicines Agency in April 2011.

In January 2013, Sanofi said it discontinued development of ombrabulin after disappointing results from phase III clinical trials.

References

References

  1. "Ombrabulin (AVE8062)". Sanofi-Aventis Oncology.
  2. (1999). "Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700". Japanese Journal of Cancer Research.
  3. (2002). "A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs". British Journal of Cancer.
  4. (15 April 2011). "Orphan Designation EU/3/11/853". European Medicines Agency.
  5. "Sanofi has 65 new compounds in development, says R&D chief".
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

experimental-cancer-drugs amino-acid-derivatives
Want to explore this topic further?

Ask Mako anything about Ombrabulin — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report